Dx Focus: Diagnovus Engauge-Cancer-DLBCL; Epigenomics Epi ProColon | GenomeWeb

Diagnovus this week launched Engauge-Cancer-DLBCL, a gene expression assay designed to aid physicians with risk stratification and treatment of patients with diffuse large B-cell lymphoma.

According to the company, Engauge-Cancer-DLBCL uses a proprietary algorithm that combines a two-gene signature (measuring expression of LMO2 and CD137) and the International Prognostic Index, producing a single risk classification. It is a standardized multi-gene reverse transcriptase-PCR assay conducted on paraffin-embedded primary DLBCL tumor tissue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.